Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Lamotrigine Extended Release
Overview
What is Lamotrigine Extended Release?
Lamotrigine extended-release, an AED of the phenyltriazine class, is chemically unrelated to existing AEDs. Its chemical name is 3,5-diamino-6-(2,3-dichlorophenyl)--triazine, its molecular formula is CHNCl, and its molecular weight is 256.09. Lamotrigine is a white to pale cream-colored powder and has a pK of 5.7. Lamotrigine is very slightly soluble in water (0.17 mg/mL at 25°C) and slightly soluble in 0.1 M HCl (4.1 mg/mL at 25°C). The structural formula is:
Lamotrigine Extended-Release Tablets are supplied for oral administration as 25 mg (round beige biconvex film-coated), 50 mg (round white biconvex film-coated), 100 mg (round brown biconvex film-coated), 200 mg (round yellow biconvex film-coated), 250 mg (round white biconvex film coated) and 300 mg (round grey biconvex film-coated) tablets. Each tablet contains the labeled amount of lamotrigine and the following inactive ingredients: hypromellose, lactose monohydrate, magnesium stearate, colloidal anhydrous silica (25 mg, 50 mg, 200 mg, 250 mg and 300 mg tablets only), methacrylic acid copolymer, talc, titanium dioxide, triethyl citrate, sodium bicarbonate, sodium laurel sulfate, iron oxide yellow (25 mg and 100 mg tablets only), iron oxide red (25 mg and 100 mg tablets only), D&C Yellow # 10 (200 mg tablet only), FD&C Yellow # 6 (200 mg tablet only) and black iron oxide (300 mg tablet only).
Lamotrigine extended-release tablet contains a modified-release eroding formulation as the core. The tablets are coated with an enteric coat and have pore forming ingredient in the coat to enable a controlled release of the drug in the acidic environment of the stomach. The combinations of the modified-release core and the enteric coat are designed to control the dissolution rate of lamotrigine over a period of approximately 12 to 15 hours, leading to a gradual increase in blood lamotrigine levels.
What does Lamotrigine Extended Release look like?
What are the available doses of Lamotrigine Extended Release?
25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other
50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other
100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other
200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other
250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other
300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other
What should I talk to my health care provider before I take Lamotrigine Extended Release?
How should I use Lamotrigine Extended Release?
Lamotrigine extended-release is indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older.
Lamotrigine Extended-Release Tablets are taken once daily, with or without food. Tablets must be swallowed whole and must not be chewed, crushed, or divided.
What interacts with Lamotrigine Extended Release?
Sorry No Records found
What are the warnings of Lamotrigine Extended Release?
Sorry No Records found
What are the precautions of Lamotrigine Extended Release?
Sorry No Records found
What are the side effects of Lamotrigine Extended Release?
Sorry No records found
What should I look out for while using Lamotrigine Extended Release?
Lamotrigine extended-release is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients .
WARNING: SERIOUS SKIN RASHES
Lamotrigine extended-release can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive immediate-release lamotrigine, there was 1 rash-related death. Lamotrigine extended-release is not approved for patients younger than 13 years. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.
The risk of serious rash caused by treatment with lamotrigine extended-release is not expected to differ from that with immediate-release lamotrigine. However, the relatively limited treatment experience with lamotrigine extended-release makes it difficult to characterize the frequency and risk of serious rashes caused by treatment with lamotrigine extended-release.
Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by lamotrigine extended-release. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of lamotrigine extended-release with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of lamotrigine extended-release, or (3) exceeding the recommended dose escalation for lamotrigine extended-release. However, cases have occurred in the absence of these factors.
Nearly all cases of life-threatening rashes caused by immediate-release lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.
Although benign rashes are also caused by lamotrigine extended-release, it is not possible to predict reliably which rashes will prove to be serious or life-threatening. Accordingly, lamotrigine extended-release should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring [see Warnings and Precautions
( )].
What might happen if I take too much Lamotrigine Extended Release?
How should I store and handle Lamotrigine Extended Release?
Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:Lamotrigine Extended-Release Tablets25 mg, round, beige, biconvex, film-coated tablet debossed with “561” on one side and “Par” on the other30 Tablets - (NDC 49884-561-11)100 Tablets - (NDC 49884-561-01)500 Tablets - (NDC 49884-561-05)50 mg, round, white, biconvex, film-coated tablet debossed with “562” on one side and “Par” on the other30 Tablets - (NDC 49884-562-11)100 Tablets - (NDC 49884-562-01)500 Tablets - (NDC 49884-562-05)100 mg, round, brown, biconvex, film-coated tablet debossed with “563” on one side and “Par” on the other30 Tablets - (NDC 49884-563-11)100 Tablets - (NDC 49884-563-01)500 Tablets - (NDC 49884-563-05)200 mg, round, yellow, biconvex, film-coated tablet debossed with “564” on one side and “Par” on the other30 Tablets - (NDC 49884-564-11)100 Tablets - (NDC 49884-564-01)500 Tablets - (NDC 49884-564-05)250 mg, round, white, biconvex, film-coated tablet debossed with “604” on one side and “Par” on the other30 Tablets – (NDC 49884-604-11)100 Tablets – (NDC 49884-604-01)500 Tablets – (NDC 49884-604-05)300 mg, round, grey, biconvex, film-coated tablet debossed with “605” on one side and “Par” on the other30 Tablets - (NDC 49884-605-11)100 Tablets - (NDC 49884-605-01)500 Tablets - (NDC 49884-605-05)Storage:
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
The precise mechanism(s) by which lamotrigine exerts its anticonvulsant action are unknown. In animal models designed to detect anticonvulsant activity, lamotrigine was effective in preventing seizure spread in the maximum electroshock (MES) and pentylenetetrazol (scMet) tests, and prevented seizures in the visually and electrically evoked after-discharge (EEAD) tests for antiepileptic activity. Lamotrigine also displayed inhibitory properties in a kindling model in rats both during kindling development and in the fully kindled state. The relevance of these models to human epilepsy, however, is not known.
One proposed mechanism of action of lamotrigine, the relevance of which remains to be established in humans, involves an effect on sodium channels. pharmacological studies suggest that lamotrigine inhibits voltage-sensitive sodium channels, thereby stabilizing neuronal membranes and consequently modulating presynaptic transmitter release of excitatory amino acids (e.g., glutamate and aspartate).
Effect of Lamotrigine on N-Methyl d-Aspartate-Receptor Mediated Activity:
Non-Clinical Toxicology
Lamotrigine extended-release is contraindicated in patients who have demonstrated hypersensitivity (e.g., rash, angioedema, acute urticaria, extensive pruritus, mucosal ulceration) to the drug or its ingredients .WARNING: SERIOUS SKIN RASHES
Lamotrigine extended-release can cause serious rashes requiring hospitalization and discontinuation of treatment. The incidence of these rashes, which have included Stevens-Johnson syndrome, is approximately 0.8% (8 per 1,000) in pediatric patients (aged 2 to 16 years) receiving immediate-release lamotrigine as adjunctive therapy for epilepsy and 0.3% (3 per 1,000) in adults on adjunctive therapy for epilepsy. In a prospectively followed cohort of 1,983 pediatric patients (aged 2 to 16 years) with epilepsy taking adjunctive immediate-release lamotrigine, there was 1 rash-related death. Lamotrigine extended-release is not approved for patients younger than 13 years. In worldwide postmarketing experience, rare cases of toxic epidermal necrolysis and/or rash-related death have been reported in adult and pediatric patients, but their numbers are too few to permit a precise estimate of the rate.
The risk of serious rash caused by treatment with lamotrigine extended-release is not expected to differ from that with immediate-release lamotrigine. However, the relatively limited treatment experience with lamotrigine extended-release makes it difficult to characterize the frequency and risk of serious rashes caused by treatment with lamotrigine extended-release.
Other than age, there are as yet no factors identified that are known to predict the risk of occurrence or the severity of rash caused by lamotrigine extended-release. There are suggestions, yet to be proven, that the risk of rash may also be increased by (1) coadministration of lamotrigine extended-release with valproate (includes valproic acid and divalproex sodium), (2) exceeding the recommended initial dose of lamotrigine extended-release, or (3) exceeding the recommended dose escalation for lamotrigine extended-release. However, cases have occurred in the absence of these factors.
Nearly all cases of life-threatening rashes caused by immediate-release lamotrigine have occurred within 2 to 8 weeks of treatment initiation. However, isolated cases have occurred after prolonged treatment (e.g., 6 months). Accordingly, duration of therapy cannot be relied upon as means to predict the potential risk heralded by the first appearance of a rash.
Although benign rashes are also caused by lamotrigine extended-release, it is not possible to predict reliably which rashes will prove to be serious or life-threatening. Accordingly, lamotrigine extended-release should ordinarily be discontinued at the first sign of rash, unless the rash is clearly not drug-related. Discontinuation of treatment may not prevent a rash from becoming life-threatening or permanently disabling or disfiguring [see Warnings and Precautions
( )].
Furosemide may increase the ototoxic potential of aminoglycoside antibiotics, especially in the presence of impaired renal function. Except in life-threatening situations, avoid this combination.
Furosemide should not be used concomitantly with ethacrynic acid because of the possibility of ototoxicity. Patients receiving high doses of salicylates concomitantly with furosemide, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.
There is a risk of ototoxic effects if cisplatin and furosemide are given concomitantly. In addition, nephrotoxicity of nephrotoxic drugs such as cisplatin may be enhanced if furosemide is not given in lower doses and with positive fluid balance when used to achieve forced diuresis during cisplatin treatment.
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of succinylcholine.
Lithium generally should not be given with diuretics because they reduce lithium's renal clearance and add a high risk of lithium toxicity.
Furosemide combined with angiotensin converting enzyme inhibitors or angiotensin II receptor blockers may lead to severe hypotension and deterioration in renal function, including renal failure. An interruption or reduction in the dosage of furosemide, angiotensin converting enzyme inhibitors, or angiotensin receptor blockers may be necessary.
Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.
Furosemide may decrease arterial responsiveness to norepinephrine. However, norepinephrine may still be used effectively.
Simultaneous administration of sucralfate and furosemide tablets may reduce the natriuretic and antihypertensive effects of furosemide. Patients receiving both drugs should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved. The intake of furosemide and sucralfate should be separated by at least two hours.
In isolated cases, intravenous administration of furosemide within 24 hours of taking chloral hydrate may lead to flushing, sweating attacks, restlessness, nausea, increase in blood pressure, and tachycardia. Use of furosemide concomitantly with chloral hydrate is therefore not recommended.
Phenytoin interferes directly with renal action of furosemide. There is evidence that treatment with phenytoin leads to decrease intestinal absorption of furosemide, and consequently to lower peak serum furosemide concentrations.
Methotrexate and other drugs that, like furosemide, undergo significant renal tubular secretion may reduce the effect of furosemide. Conversely, furosemide may decrease renal elimination of other drugs that undergo tubular secretion. High-dose treatment of both furosemide and these other drugs may result in elevated serum levels of these drugs and may potentiate their toxicity as well as the toxicity of furosemide.
Furosemide can increase the risk of cephalosporin-induced nephrotoxicity even in the setting of minor or transient renal impairment.
Concomitant use of cyclosporine and furosemide is associated with increased risk of gouty arthritis secondary to furosemide-induced hyperurecemia and cyclosporine impairment of renal urate excretion.
High doses (> 80 mg) of furosemide may inhibit the binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by an overall decrease in total thyroid hormone levels.
One study in six subjects demonstrated that the combination of furosemide and acetylsalicylic acid temporarily reduced creatinine clearance in patients with chronic renal insufficiency. There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when furosemide was used in conjunction with NSAIDs.
Literature reports indicate that coadministration of indomethacin may reduce the natriuretic and antihypertensive effects of furosemide in some patients by inhibiting prostaglandin synthesis. Indomethacin may also affect plasma renin levels, aldosterone excretion, and renin profile evaluation. Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
The risk of serious rash caused by treatment with lamotrigine extended-release is not expected to differ from that with the immediate-release lamotrigine . However, the relatively limited treatment experience with lamotrigine extended-release makes it difficult to characterize the frequency and risk of serious rashes caused by treatment with lamotrigine extended-release.
Pediatric Population:
There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in pediatric patients. In pediatric patients who used valproate concomitantly, 1.2% (6 of 482) experienced a serious rash compared with 0.6% (6 of 952) patients not taking valproate.
Lamotrigine extended-release is not approved in patients younger than 13 years.
Adult Population:
Among the rashes leading to hospitalization were Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, and those associated with multiorgan hypersensitivity [see Warnings and Precautions ()].
There is evidence that the inclusion of valproate in a multidrug regimen increases the risk of serious, potentially life-threatening rash in adults. Specifically, of 584 patients administered immediate-release formulation of lamotrigine with valproate in epilepsy clinical trials, 6 (1%) were hospitalized in association with rash; in contrast, 4 (0.16%) of 2,398 clinical trial patients and volunteers administered the immediate-release formulation of lamotrigine in the absence of valproate were hospitalized.
Patients With History of Allergy or Rash to Other Antiepileptic Drugs:
The following adverse reactions are described in more detail in the section of the label:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
518Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).